The Filing Desk

Inhibrx Biosciences vs Longeveron

Inhibrx Biosciences INBX · Longeveron LGVN · Biotechnology

Inhibrx Biosciences reported revenue of $1 million in fiscal 2025, about the same as Longeveron's $1 million in fiscal 2025. Inhibrx Biosciences' revenue grew 550.0% in its latest year, and Longeveron's fell 49.9%. Inhibrx Biosciences had an operating margin of -10386.5%, against -1942.2% at Longeveron. Free cash flow was −$130 million at Inhibrx Biosciences and −$19 million at Longeveron.

Side by side

Inhibrx BiosciencesLongeveron
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$1M$1M
Revenue growth550.0%−49.9%
Revenue growth a year, last 5 years—−26.5%
Gross margin—67.0%
Operating margin−10,386.5%−1,942.2%
Net margin−10,773.5%−1,893.6%
Free cash flow−$130M−$19M
Free cash flow margin−9,986.5%−1,575.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count3.4%86.8%
Last close$74.33$1.82
P/E at the last close——
Insider trades, last 12 monthsbought $5.5 million, sold $279,015—
Piotroski F-score2 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Inhibrx BiosciencesLongeveron
Operating margin
Percent of revenue
Inhibrx BiosciencesLongeveron
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Inhibrx BiosciencesLongeveron

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Inhibrx Biosciences and Longeveron pages.